Skip to main content
Terug
Watch Compare

LIPELLA PHARMACEUTICALS INC.

Datakwaliteit: 100%
LIPO
OTC Manufacturing Chemicals
€ 0,04
▲ € 0,01 (59,09%)
Marktkapitalisatie: 161.729,0
Prijs
€ 0,04
Marktkapitalisatie
161.729,0
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -4,78 M
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)19,29%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-252,04%
Onder sectorgemiddelde (-53,34%)
ROIC-182,62%
Net Margin-1367,37%
Op. Margin-1387,94%

Veiligheid

Debt / Equity
N/A
Current Ratio3,24
Interest CoverageN/A

Waardering

PE (TTM)
-0,03
Boven sectorgemiddelde (-1,47)
P/B Ratio0,11
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 0,0 -1,5
P/B 0,1 1,6
ROE % -252,0 -53,3
Net Margin % -1367,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42024 -€ 2,43 -€ 1,19 +51,0%
Q32024 -€ 0,96 -€ 1,29 -34,4%
Q22024 -€ 1,04 -€ 0,96 +7,7%
Q12024 N/A -€ 1,28 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19,29% Revenue Growth (3Y) 70,66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 389.783,0 Net Income (TTM) -5,33 M
ROE -252,04% ROA -175,61%
Gross Margin N/A Operating Margin -1387,94%
Net Margin -1367,37% Free Cash Flow (TTM) -4,78 M
ROIC -182,62% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,24
Interest Coverage N/A Asset Turnover 0,13
Working Capital 1,44 M Tangible Book Value 1,49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,03 Forward P/E N/A
P/B Ratio 0,11 P/S Ratio 0,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2952,92%
Market Cap 161.729,0 Enterprise Value -1,69 M
Per Share
EPS (Diluted TTM) -2,26 Revenue / Share 0,08
FCF / Share -1,03 OCF / Share -1,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 89,61%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 536.357,0 449.617,0 184.156,0
Net Income -5,02 M -4,62 M -2,60 M
EPS (Diluted) -4,79 -0,77 -0,64
Gross Profit — — —
Operating Income -5,08 M -4,75 M -2,59 M
EBITDA — — —
R&D Expenses 3,61 M 3,04 M 2,55 M
SG&A Expenses — — —
D&A 2.886,0 1.685,0 —
Interest Expense 10.848,0 10.848,0 9.612,0
Income Tax — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 2,67 M 3,58 M 5,95 M
Total Liabilities 754.417,0 432.726,0 1,27 M
Shareholders' Equity 1,92 M 3,14 M 4,68 M
Total Debt — — —
Cash & Equivalents 2,18 M 3,29 M 5,12 M
Current Assets 2,62 M 3,43 M 5,80 M
Current Liabilities 754.417,0 385.355,0 1,18 M